This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Manfredi C, Bologna E, Licari LC. Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. Int J Impot Res. 2023;1–2. https://doi.org/10.1038/s41443-023-00811-4.
Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472–7.
Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis. Int J Impot Res. 2022. https://doi.org/10.1038/S41443-022-00651-8.
Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Pharm Ther. 2013;38:407.
Durukan E, Kraglund R, Rashid SA, Thorkilgaard T, Jensen CFS, Fode M. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s Disease: a retrospective cohort study. Int J Impot Res. 2024: 1–4. https://doi.org/10.1038/s41443-023-00810-5.
Joseph J, Ziegelmann MJ, Alom M, Savage J, Köhler TS, Trost L. Outcomes of RestoreX penile traction therapy in men with Peyronie’s disease: results from open label and follow-up phases. J Sex Med. 2020;17:2462–71.
Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106:1178–1180.
Author information
Authors and Affiliations
Contributions
ED: Manuscript writing and editing, CFSJ: Manuscript reviewing and editing, MF: Manuscript reviewing, editing and supervision.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Durukan, E., Jensen, C.F.S. & Fode, M. Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. Int J Impot Res 36, 297–298 (2024). https://doi.org/10.1038/s41443-024-00872-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-024-00872-z